scholarly journals Bristol Stool Scale

2020 ◽  
Author(s):  
Keyword(s):  
Bristol Stool Scale

scholarly journals Effect of probiotics on stool characteristic of bottle fed infants

2019 ◽  
Vol 9 (3) ◽  
pp. 157
Author(s):  
Yoo Mi Lee ◽  
Young Sun Cho ◽  
Su Jin Jeong
Keyword(s):  
Breast Milk ◽  
South Korea ◽  
Lactobacillus Plantarum ◽  
Medical Center ◽  
Sole Source ◽  
Primary Objective ◽  
Stool Frequency ◽  
Once Daily ◽  
Bristol Stool Scale ◽  
Secondary Objective

Background: Approximately 70% of all newborns in South Korea are fed a commercial formula as their sole source of nutrition or as a supplement to breast milk. It is common for many formula-fed infants to be switched from one formula to another because of perceived abnormalities in stooling patterns (too much/too little, too hard/too loose). Also, probiotics may have been recommended by a clinician or practitioner when there is thought to be a problem with the babies stool based on many reports.Aims: The primary objective of this study was to determine whether probiotic (nLp-nF1) exposure during the first 6 months of life is safe. The secondary objective was to assess if nF1 exposure correlated with changes in formula-fed infants’ stool characteristics.Result: We recruited 49 healthy formula-fed infants aged 0-6 months from Bundang Cha Medical Center. Infants were given a 14-day supply of probiotics (nf1: Lactobacillus plantarum 2.5 X 1010/g/pack, 2 pack/day). The overall rate of stool change after probiotics is 83% (41/49). Among them, 75.6% (31/41) participants answered fairly about the change of stool characteristics. The significant change of stool frequency, stool color and flatulence after probiotics intervention was reported. The number of infants who defecated once daily was increased from 53% (26 of 49) to 77.5% (38 of 49) (P=0.075). Mustard yellow colored feces increased from 22 to 40 (p=0.018). Only 9 out of 20 infants with flatulence (>3 times) showed persistence of symptoms after probiotics (p<0.001). After taking probiotics, Bristol Stool Scale 4-5 stool was reported from 23 to 37(p=0.018).Conclusion: By taking probiotics, the color of the stool changed, and the incidence of flatulence production decreased. Although the results are not statistically significant, the quality and quantity of stool improved according to the Bristol Stool Scale.Keywords: Probiotics, Bristol Stool Scale, stool

Bristol Stool Scale as a Determinant of Hepatic Encephalopathy Management in Patients With Cirrhosis

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Nikki K. Duong ◽  
Shreesh Shrestha ◽  
Dan Park ◽  
Omer Shahab ◽  
Andrew Fagan ◽  
...  
Keyword(s):  
Hepatic Encephalopathy ◽  
Bristol Stool Scale

scholarly journals Prospective switch study comparing two irrigation systems for transanal irrigation in children

2021 ◽  
Vol 84 (2) ◽  
pp. 295-298
Author(s):  
K Van Renterghem ◽  
M Sladkov ◽  
L Matthyssens ◽  
D Van de Putte ◽  
P Pattyn ◽  
...  
Keyword(s):  
Rectal Balloon ◽  
Patient Control ◽  
Transanal Irrigation ◽  
Control Switch ◽  
Parametric Statistics ◽  
Bristol Stool Scale ◽  
Selection For ◽  
Irrigation Volume ◽  
Switch Study

Background and study aims: Transanal irrigation (TAI) is used in children to treat constipation and incontinence. Belgium has 2 systems available: Colotip® (cheaper, however not designed for TAI) or Peristeen®. Patients and methods: This patient-control switch study is the first to compare 2 TAI systems. Children regularly using Colotip® for TAI were asked to participate, after consent, a visual analogue scale (VAS) rating the system and a 2-week diary (fecal continence, self-reliance, time spent on the toilet, pain, Bristol stool scale, irrigation volume and frequency of enema) were completed. Non-parametric statistics were used. Results: Out of 26 children using Colotip®, 18 (69%) children participated and 5 refused (fear n=1, satisfaction Colotip® system n=7). Of these 18 children (interquartile range: 3-18 years, median 12.5 years, 9 girls) 5 patients stopped Peristeen® (pain n=1, fear n=1 and balloon loss n=3) and 2 were lost from follow up. Dropouts and included patients showed no statistical difference. In the 11 remaining patients, pseudo-continence (p 0.015), independence (p 0.01) and VAS score (p 0.007) were significantly better with Peristeen®, no difference was found in time spent on the toilet (p 0.288) and presence of pain (p 0.785). Conclusions: In children Peristeen® offered significantly higher pseudo-continence and independency. 30% refused participation because of satisfaction with the Colotip® and 30% spina bifida patients reported rectal balloon loss due to sphincter hypotony. To diminish Peristeen® failure, a test-catheter could be of value. Considering Colotip® satisfaction, both systems should be available. Patient selection for Peristeen® needs further research.

scholarly journals 1626The relationship of Bristol Stool Scale to Clostridium difficile infection

2014 ◽  
Vol 1 (suppl_1) ◽  
pp. S434-S434
Author(s):  
Daniel Caroff ◽  
Paul Edelstein ◽  
Keith Hamilton ◽  
David Pegues
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Bristol Stool Scale ◽  
Relationship Of

scholarly journals Lactobacillus acidophilussupplementation in human subjects and their resistance to enterotoxigenicEscherichia coliinfection

2013 ◽  
Vol 111 (3) ◽  
pp. 465-473 ◽  
Author(s):  
A. C. Ouwehand ◽  
S. J. M. ten Bruggencate ◽  
A. J. Schonewille ◽  
E. Alhoniemi ◽  
S. D. Forssten ◽  
...  
Keyword(s):  
Human Subjects ◽  
Placebo Treatment ◽  
Oral Challenge ◽  
Adaptation Period ◽  
Double Blind ◽  
Faecal Calprotectin ◽  
Probiotic Treatment ◽  
Scale Scores ◽  
Bristol Stool Scale ◽  
Etec Infection

To assess the effect ofLactobacillus acidophilus(American Type Culture Collection (ATCC) 700396) on enterotoxigenicEscherichia coli(ETEC) infection, in the present study, a parallel, double-blind, placebo-controlled 4-week intervention was performed in healthy males. The subjects largely consumed their habitual diet, but had to abstain from consuming dairy foods generally high in Ca. The subjects were randomised into theL. acidophilus(dose 109colony-forming units twice daily;n20) or the placebo (n19) group. After an adaptation period of 2 weeks, the subjects were orally infected with a live, but attenuated, ETEC vaccine, able to induce mild, short-lived symptoms. Before and after the challenge, the subjects recorded stool consistency, bowel habits, and frequency and severity of gastrointestinal complaints. The ETEC challenge led to a significant increase in faecal output on the 2nd day and a concomitant increase in Bristol stool scale scores. Likewise, abdominal pain, bloating, flatulence, fever, headache and nausea peaked 1 d after the oral challenge. The concentrations of faecal calprotectin and IgA peaked 2 d after and that of serum IgM peaked 9 and 15 d after the oral challenge. The concentrations of serum IgA and IgG were unaffected. The ETEC challenge led to a reduction in the number ofBacteroides–Prevotella,Bifidobacterium,Clostridiumcluster XIVab and total faecal bacteria. Probiotic treatment was associated with a larger increase in Bristol stool scale scores and more fever, headache and nausea after the ETEC challenge compared with the placebo treatment. These differences were, however, small and with substantial variation within the groups. Oral application of an attenuated live ETEC vaccine provides a useful model for food-borne infections. Supplementation withL. acidophilusATCC 700396, however, was ineffective in reducing ETEC infection symptoms in healthy men.

Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial

2019 ◽  
Vol 10 (6) ◽  
pp. 629-639 ◽  
Author(s):  
Y. Sakai ◽  
N. Seki ◽  
K. Hamano ◽  
H. Ochi ◽  
F. Abe ◽  
...  
Keyword(s):  
Primary Outcome ◽  
Crossover Trial ◽  
Random Order ◽  
Japanese Women ◽  
Double Blind ◽  
Colony Forming Units ◽  
Significant Difference ◽  
Faecal Consistency ◽  
Bristol Stool Scale ◽  
Trial Participants

Sixty healthy Japanese women with a defaecation frequency of 2-4 times/week participated in this randomised, double-blind crossover trial. Participants received 2 g/day lactulose for 2 weeks and placebo in a random order, separated by a washout period of 3 weeks. Eight participants were excluded who did not satisfy the conditions, and therefore data from 52 were analysed. The primary outcome was defaecation frequency and the secondary outcomes were the number of defaecation days, faecal consistency, faecal volume, and the number and percentage of Bifidobacterium in faeces. The defaecation frequency (times/week) was significantly higher during lactulose (4.28±0.23) than placebo (3.83±0.23) treatment (delta (Δ) 0.45 [95% confidence interval (CI) 0.10-0.80], P=0.013). The defaecation days (days/week) was significantly higher during lactulose (3.77±0.17) than placebo (3.47±0.17) treatment (Δ0.30 [95% CI 0.04-0.56], P=0.024). Faecal consistency using the Bristol Stool Scale (/defaecation) was significantly higher during lactulose (3.84±0.10) than placebo (3.68±0.10) treatment (Δ0.16 [95% CI 0.00-0.31], P=0.044). Faecal volume (/week) was significantly higher during lactulose (21.73±3.07) than placebo (17.65±3.07) treatment (Δ4.08 [95% CI 0.57-7.60], P=0.024). The number of Bifidobacterium in faeces (log colony forming units/g faeces) was significantly higher during lactulose (9.53±0.06) than placebo (9.16±0.06) treatment (Δ0.37 [95% CI 0.23-0.49], P<0.0001). The percentage of Bifidobacterium in faeces was also significantly higher during lactulose (25.3±1.4) than placebo (18.2±1.4) treatment (Δ7.1 [95% CI 2.9-11.4], P=0.0014). Finally, straining at defaecation (/defaecation) during lactulose (3.62±0.24) treatment was significantly lower than during placebo (3.97±0.24) treatment (Δ0.35 [95% CI -0.69 – -0.02], P=0.037). No significant difference was observed between lactulose and placebo with regard to flatulence. Severe adverse effects did not occur. Thus, oral ingestion of 2 g/day lactulose had a prebiotic effect, increasing the number and percentage of bifidobacteria in faeces, softening the faeces, and increasing defaecation frequency, but without increasing flatulence.

Tu1756 Only Fair Agreement Exists Between the Bristol Stool Scale and Parental Report of Stool Consistency in Young Children

2016 ◽  
Vol 150 (4) ◽  
pp. S935
Author(s):  
Ilan J. Koppen ◽  
Miguel Saps ◽  
Marc A. Benninga ◽  
Carlo Di Lorenzo ◽  
Carlos A. Velasco-Benitez
Keyword(s):  
Young Children ◽  
Fair Agreement ◽  
Stool Consistency ◽  
Parental Report ◽  
Bristol Stool Scale

Amsterdam infant stool scale is more useful for assessing children who have not been toilet trained than Bristol stool scale

2013 ◽  
Vol 103 (2) ◽  
pp. e91-e92 ◽  
Author(s):  
A Ghanma ◽  
K Puttemans ◽  
M Deneyer ◽  
MA Benninga ◽  
Y Vandenplas
Keyword(s):  
Bristol Stool Scale

T1133 Validation of a Modified Bristol Stool Scale - Inter-Rater Reliability Amongst Pediatric Gastroenterologists

2009 ◽  
Vol 136 (5) ◽  
pp. A-506
Author(s):  
Bruno P. Chumpitazi ◽  
Erica Weidler ◽  
Danita I. Czyzewski ◽  
Mariella Lane ◽  
Robert J. Shulman
Keyword(s):  
Rater Reliability ◽  
Bristol Stool Scale
Sign in / Sign up

Export Citation Format

Share Document